Related Experiment Video
Updated: Jul 10, 2025

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Angina and Non-Obstructive Coronary Artery (ANOCA) Patients with Coronary Vasomotor Disorders
Sarena La1,2,3, Rosanna Tavella1,2,3, Jing Wu1
1School of Medicine, Faculty of Health Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.
Insights
Diagnosing coronary vasomotor disorders in Angina and Non-Obstructive Coronary Artery (ANOCA) patients improves symptom management. Identifying these conditions leads to more emergency visits and readmissions for chest pain, highlighting the need for personalized care.
Area of Science:
- Cardiology
- Vascular Medicine
- Diagnostic Imaging
Background:
- Angina and Non-Obstructive Coronary Artery (ANOCA) patients often receive a diagnosis of unspecified chest pain.
- Functional coronary angiography can identify coronary vasomotor disorders, but their impact on ANOCA patient outcomes is unclear.
Purpose of the Study:
- To compare the outcomes of ANOCA patients diagnosed with coronary vasomotor disorders versus those discharged with unspecified chest pain.
Main Methods:
- Analysis of the CADOSA registry (2012-2018) including 7555 symptomatic patients undergoing elective angiography.
- Identification of 30% ANOCA patients (stenosis <50%), with 9% diagnosed with coronary vasomotor disorders.
Main Results:
- Patients with coronary vasomotor disorders were younger and had similar female prevalence.
- While all-cause mortality was similar, those with diagnosed disorders had significantly higher rates of emergency department visits (39% vs 15%) and readmissions (30% vs 10%) for chest pain within 3 years.
Conclusions:
- Diagnosing coronary vasomotor disorders in ANOCA patients is crucial for personalized management.
- Despite similar mortality, identified disorders correlate with increased healthcare utilization for chest pain symptoms.
Abstract:
Angina and Non-Obstructive Coronary Artery (ANOCA) patients often lack a clear explanation for their symptoms, and are frequently discharged with the label of "unspecified chest pain", despite the availability of functional coronary angiography (provocative spasm and microvascular function testing) to identify potential underlying coronary vasomotor disorders. This study compared the outcomes of ANOCA patients with a coronary vasomotor disorder diagnosis post elective coronary angiography to patients discharged with unspecified chest pain. Using the CADOSA (Coronary Angiogram Database of South Australia) registry, consecutive symptomatic patients (n = 7555) from 2012 to 2018 underwent elective angiography; 30% had ANOCA (stenosis <50%). Of this cohort, 9% had documented coronary vasomotor disorders diagnosed, and 91% had unspecified chest pain. Patients with coronary vasomotor disorders were younger and had a similar female prevalence compared with those with unspecified chest pain. New prescriptions of calcium channel blockers and long-acting nitrates were more common for the coronary vasomotor cohort at discharge. In the 3 years following angiography, both groups had similar all-cause mortality rates. However, those with coronary vasomotor disorders had higher rates of emergency department visits for chest pain (39% vs. 15%, p < 0.001) and readmissions for chest pain (30% vs. 10%, p < 0.001) compared with those with unspecified chest pain. This real-world study emphasizes the importance of identifying high-risk ANOCA patients for personalized management to effectively address their symptoms.
Related Concept Videos
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: β-Blockers
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

